Bupropion as a modulator of drug activity

• US 10,058,518 B2
• Filed: 08/28/2017
• Issued: 08/28/2018
• Est. Priority Date: 11/05/2013
• Status: Active Grant

• Current Assignee: Antecip Bioventures II LLC
• Original Assignee: Antecip Bioventures II LLC
• Inventors: Tabuteau, Herriot
• Primary Examiner(s): Baek, Bong-Sook
• Application Number:
  US15/688,660
• Publication Number:
  US 20170354619A1
• Time in Patent Office: 365 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/15 Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
• CPC Class Codes: A61K 31/381 having five-membered rings
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine

Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claims

1. A method of reducing a dextromethorphan trough effect, comprising administering a combination of a bupropion and a dextromethorphan once or twice a day for at least eight consecutive days to a human being in need of treatment with dextromethorphan, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the daily dose of the dextromethorphan is about 40 mg to about 140 mg, and wherein, on the eighth consecutive day of administering the combination of the bupropion and the dextromethorphan, the human being has a C_min of dextromethorphan that is at least about 20 ng/mL, and the C_min of dextromethorphan is at least about 20 times a reference C_min of dextromethorphan that would result from administering the daily dose of the same amount of the dextromethorphan without the bupropion to the human being for eight consecutive days.

2. The method of claim 1, wherein the daily dose of the dextromethorphan is about 90 mg.

3. The method of claim 1, wherein a single dose of the dextromethorphan is about 44 mg to about 46 mg.

4. The method of claim 2, wherein about 200 mg to about 250 mg of the bupropion is administered per day.

5. The method of claim 1, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 45 ng/mL.

6. The method of claim 1, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 55 ng/mL.

7. The method of claim 1, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 75 ng/mL.

8. The method of claim 1, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 30 times the C_max of dextromethorphan that would result from administering the same amount of the dextromethorphan daily without the bupropion for eight consecutive days.

9. The method of claim 4, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 45 ng/mL.

10. The method of claim 4, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 55 ng/mL.

11. The method of claim 4, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 75 ng/mL.

12. The method of claim 4, wherein the human being has a C_max of dextromethorphan on the eighth day of at least about 30 times the C_max of dextromethorphan that would result from administering the daily dose of the same amount of the dextromethorphan without the bupropion to the human being for eight consecutive days.

13. The method of claim 1, wherein the bupropion is deuterium-modified.

14. The method of claim 2, wherein the dextromethorphan is deuterium-modified.

15. The method of claim 1, wherein the combination of the bupropion and the dextromethorphan is administered as a solid or liquid, in a single oral dosage form.

16. The method of claim 15, wherein the single oral dosage form is a solid.

17. The method of claim 16, wherein the single solid oral dosage form further comprises magnesium stearate.

18. The method of claim 16, wherein the single solid oral dosage form further comprises hydroxypropyl methylcellulose.

19. The method of claim 16, wherein the single solid oral dosage form further comprises microcrystalline cellulose.

20. The method of claim 16, wherein the single solid oral dosage form is a tablet, a troche, a pill or a capsule.

21. The method of claim 12, wherein the combination of the bupropion and the dextromethorphan is administered to the human being once a day for at least 30 consecutive days or twice a day for at least 30 consecutive days.

22. The method of claim 1, wherein the combination of the bupropion and the dextromethorphan is administered to the human being once a day for at least 60 consecutive days or twice a day for at least 60 consecutive days.

23. The method of claim 9, wherein the human being has an AUC_0-12 of the dextromethorphan on the eighth day of at least about 400 ng·

hr/mL.

24. The method of claim 9, wherein the human being has an AUC_0-12 of the dextromethorphan on the eighth day of at least about 700 ng·

hr/mL.

25. The method of claim 9, wherein the human being has an AUC_0-12 of the dextromethorphan on the eighth day of about 400 ng·

hr/mL to about 600 ng·

hr/mL.

26. The method of claim 9, wherein the human being has an AUC_0-12 of the dextromethorphan on the eighth day of about 700 ng·

hr/mL to about 1,100 ng·

hr/mL.

27. The method of claim 9, wherein the human being is not suffering from neuropathic pain.